X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (365) 365
Book Review (51) 51
Conference Proceeding (32) 32
Publication (25) 25
Book / eBook (5) 5
Book Chapter (4) 4
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (191) 191
humans (179) 179
hematology (133) 133
multiple myeloma (110) 110
aged (98) 98
male (98) 98
oncology (98) 98
female (96) 96
multiple myeloma - drug therapy (87) 87
bortezomib (83) 83
middle aged (81) 81
antineoplastic combined chemotherapy protocols - therapeutic use (66) 66
aged, 80 and over (53) 53
stem-cell transplantation (53) 53
survival (52) 52
dexamethasone (51) 51
prognosis (48) 48
abridged index medicus (44) 44
adult (44) 44
multiple myeloma - pathology (44) 44
multiple myeloma - mortality (43) 43
treatment outcome (43) 43
multiple myeloma - therapy (42) 42
therapy (41) 41
risk factors (39) 39
antineoplastic combined chemotherapy protocols - adverse effects (38) 38
lenalidomide (38) 38
thalidomide - analogs & derivatives (35) 35
multiple myeloma - diagnosis (33) 33
thalidomide (32) 32
care and treatment (30) 30
analysis (27) 27
disease progression (27) 27
multiple myeloma - genetics (27) 27
boronic acids - administration & dosage (26) 26
follow-up studies (26) 26
pyrazines - administration & dosage (26) 26
antineoplastic agents - therapeutic use (25) 25
hemic and lymphatic diseases (24) 24
clinical trials (23) 23
hematology, oncology and palliative medicine (22) 22
melphalan (22) 22
melphalan - administration & dosage (22) 22
minimal residual disease (22) 22
multiple-myeloma (22) 22
disease-free survival (21) 21
medicine, general & internal (21) 21
prednisone (21) 21
thalidomide - administration & dosage (21) 21
transplantation (21) 21
kaplan-meier estimate (20) 20
prednisone - administration & dosage (20) 20
transplantation, autologous (20) 20
cancer (19) 19
dexamethasone - administration & dosage (19) 19
diagnosis (19) 19
elderly-patients (19) 19
patients (19) 19
thalidomide - therapeutic use (19) 19
antineoplastic combined chemotherapy protocols - administration & dosage (18) 18
immunophenotyping (18) 18
research (18) 18
risk (18) 18
chemotherapy (17) 17
drug therapy (17) 17
flow cytometry (17) 17
monoclonal gammopathy (17) 17
carfilzomib (16) 16
criteria (16) 16
drug administration schedule (16) 16
progression (16) 16
recurrence (16) 16
spain (16) 16
time factors (16) 16
undetermined significance (16) 16
boronic acids - adverse effects (15) 15
development and progression (15) 15
disease (15) 15
induction (15) 15
initial treatment (15) 15
lenalidomide plus dexamethasone (15) 15
myeloma (15) 15
peripheral neuropathy (15) 15
prevalence (15) 15
pyrazines - adverse effects (15) 15
quality of life (15) 15
cross-sectional studies (14) 14
dexamethasone - therapeutic use (14) 14
plasma-cells (14) 14
plus dexamethasone (14) 14
retrospective studies (14) 14
stem cell transplantation (14) 14
survival analysis (14) 14
clinical trials as topic (13) 13
genetic aspects (13) 13
maintenance (13) 13
medical research (13) 13
open-label (13) 13
survival rate (13) 13
thalidomide - adverse effects (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 7, pp. 621 - 631
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs.... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | RISK | MULTICENTER | THERAPY | ELOTUZUMAB | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Refractory materials | Inhibitors | Interactive systems | Response rates | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 5, pp. 438 - 447
Journal Article
American Journal of Hematology, ISSN 0361-8609, 08/2015, Volume 90, Issue 8, p. 146
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2008, Volume 359, Issue 9, pp. 906 - 917
Journal Article